Alx oncology to present at the 41st annual j.p. morgan healthcare conference

South san francisco, calif., jan. 03, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies to block the cd47 checkpoint pathway, today announced that jaume pons, ph.d., founder, president and chief executive officer, will present a company overview at the 41st annual j.p. morgan healthcare conference on tuesday, january 10 at 10:30 am pt at the westin st. francis in san francisco.
ALXO Ratings Summary
ALXO Quant Ranking